Skip to content

Replimune Group REPL Non-Cash Lease Expense

Non-Cash Lease Expense at other companies

Immunome logo
ImmunomeIMNM
$150K+30.4%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$455K-14.6%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$2M0.0%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$972K-4.0%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$26K+18.2%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's non-cash lease expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's non-cash lease expense?
Replimune Group (REPL) reported non-cash lease expense of $194K in Q4 2025.
How has Replimune Group's non-cash lease expense changed year-over-year?
Replimune Group's non-cash lease expense increased by 12.1% year-over-year, from $173K to $194K.
What does non-cash lease expense mean?
Non-cash portion of operating lease cost — the difference between straight-line lease expense and actual cash rent payments.